Table 1_Burden of hypertensive heart disease attributed to metabolic factors from 1990 to 2021 at global, regional, and national levels: an analysis of the global burden of disease... حسب Bo Peng (273834)

"…</p>Results<p>In 2021, deaths and DALYs due to HSBP and high BMI significantly increased compared to 1990. However, the ASMR for HSBP-related HHD [EAPC: −0.68; 95% confidence interval (CI): −0.77 to −0.58] and ASDR (EAPC: −0.90; 95% CI: −0.99 to −0.80) showed a decreasing trend, while the ASMR for BMI-related HHD (EAPC: 0.33; 95% CI: 0.27–0.39) and ASDR (EAPC: 0.15; 95% CI: 0.10–0.21) exhibited an increasing trend. …"

Table 1_IP-10 acts early in CV-A16 infection to induce BBB destruction and promote virus entry into the CNS by increasing TNF-α expression.docx حسب Yajie Hu (550783)

"…<p>The mechanisms underlying pathological changes in the central nervous system (CNS) following Coxsackievirus A16 (CV-A16) infection have not yet been elucidated. …"

This is raw data of IL-1β real-time PCR. حسب Farzad Nasri (8941850)

"…</p><p>Results</p><p>The proliferation of U937 cells reduced significantly in the presence of IFN-β, while it did not show a remarkable change following treatment with Vit D. …"

This is raw data of β-catenin real-time PCR. حسب Farzad Nasri (8941850)

"…</p><p>Results</p><p>The proliferation of U937 cells reduced significantly in the presence of IFN-β, while it did not show a remarkable change following treatment with Vit D. …"

Table 2_Burden of hypertensive heart disease attributed to metabolic factors from 1990 to 2021 at global, regional, and national levels: an analysis of the global burden of disease... حسب Bo Peng (273834)

"…</p>Results<p>In 2021, deaths and DALYs due to HSBP and high BMI significantly increased compared to 1990. However, the ASMR for HSBP-related HHD [EAPC: −0.68; 95% confidence interval (CI): −0.77 to −0.58] and ASDR (EAPC: −0.90; 95% CI: −0.99 to −0.80) showed a decreasing trend, while the ASMR for BMI-related HHD (EAPC: 0.33; 95% CI: 0.27–0.39) and ASDR (EAPC: 0.15; 95% CI: 0.10–0.21) exhibited an increasing trend. …"

Details of the primers applied in real-time PCR. حسب Farzad Nasri (8941850)

"…</p><p>Results</p><p>The proliferation of U937 cells reduced significantly in the presence of IFN-β, while it did not show a remarkable change following treatment with Vit D. …"

This is raw data of viability data. حسب Farzad Nasri (8941850)

"…</p><p>Results</p><p>The proliferation of U937 cells reduced significantly in the presence of IFN-β, while it did not show a remarkable change following treatment with Vit D. …"

Supplementary file 1_Analysis of microbial composition in different dry skin areas of Beijing women.docx حسب Jingtao Wang (828021)

"…At the genus level, the relative abundance of Streptococcus was significantly increased in the dry skin group, whereas a decreasing trend was observed for Cutibacterium. …"

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …"